Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 17

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 17
---
, Inc., a Nasdaq-listed biopharmaceutical company and since December 2018, Ms. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. From March 2021 until May 2022, Ms. Okey served as a member of the board of directors of Orphazyme, a company based in Denmark. From August 2023 until acquisition by Novo Holdings in December 2024, Ms. Okey served on the board of directors of Catalent, Inc. Beginning February 2024 and ongoing, Ms. Okey serves on the board of directors of City of Hope Medical Center. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University and a M.S. degree in Immunology and Medical Microbiology from Wright State University. Ms. Okey’s executive leadership experience in the life science industry and service on various biopharmaceutical company boards contributed to our board of directors’ conclusion that she should serve as a director of our company. Term Expiring at the 2027 Annual Meeting of Stockholders (Class III)

| Name                    |     | Age |     | Present Position with Crinetics Pharmaceuticals, Inc. |
| Camille Bedrosian, M.D. |     |  72 |     | Director                                              |
| Wendell Wierenga, Ph.D. |     |  77 |     | Chairperson of the Board of Directors                 |

<div align='center'>10</div>

Camille Bedrosian, M.D.joined our board of directors in September 2020. Since November 2023, Dr. Bedrosian has served as Chief Medical Officer or Amylyx Pharmaceuticals, Inc. From January 2018 through 2023, Dr. Bedrosian served as Executive Vice President and Chief Medical Officer at Ultragenyx Pharmaceutical Inc. Dr. Bedrosian previously served as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc., a biopharmaceutical company, from May 2008 to January 2018. Between September 2002 and April 2008, she served as Vice President and Chief Medical Officer at Ariad Pharmaceuticals, Inc., an oncology company. From 1997 to 2002, Dr. Bedros